The invention relates to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid, and to a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor).
该发明涉及(R)-3-[6-
氨基吡啶-3-基]-2-(1-环己基-
1H-咪唑-4-基)-
丙酸的钠盐,以及(R)-3-[6-
氨基吡啶-3-基]-2-(1-环己基-
1H-咪唑-4-基)-
丙酸的钠盐,其以结晶形式或至少部分结晶形式存在,以及制备该盐的方法,使用这种盐治疗因TAFIa酶(活化凝血酶可活化纤溶
抑制剂)
抑制剂的给药而改善的病患的方法。